(NASDAQ: TBPH) Theravance Biopharma's forecast annual revenue growth rate of 12.7% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 108.37%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 25.15%.
Theravance Biopharma's revenue in 2025 is $77,205,000.On average, 8 Wall Street analysts forecast TBPH's revenue for 2025 to be $5,830,327,238, with the lowest TBPH revenue forecast at $4,713,313,693, and the highest TBPH revenue forecast at $8,253,209,188. On average, 8 Wall Street analysts forecast TBPH's revenue for 2026 to be $5,348,369,635, with the lowest TBPH revenue forecast at $3,572,731,061, and the highest TBPH revenue forecast at $9,423,605,708.
In 2027, TBPH is forecast to generate $5,565,426,821 in revenue, with the lowest revenue forecast at $4,109,229,947 and the highest revenue forecast at $6,790,213,540.